Quebec SEAO #20177532

Edwards SAPIEN 3 ULTRA RESILIA valves and TAVI/TAVR equipment

Santé Québec’s Nord-de-l’Île-de-Montréal university establishment plans to procure valves and equipment for TAVI/TAVR procedures. - Government buyer: Santé Québec, Nord-de-l’Île-de-Montréal – Universitaire. - OEM and intended supplier: Edwards Lifesciences; Edwards Lifesciences Canada Inc. is identified as the intended direct-award supplier and the only supplier known to meet the establishment’s clinical and technical requirements. - Products requested: - Edwards Lifesciences SAPIEN 3 ULTRA RESILIA percutaneous valves for transcatheter aortic valve replacement (TAVI/TAVR). - Related TAVI/TAVR valve accessories and deployment systems. - Notable product requirement: The valves use Resilia-treated bovine pericardial tissue, which is intended to reduce calcification and improve durability. - Quantities and part numbers: Not specified. - Period of performance: 36 months, with two one-year renewal periods, for a potential total of 60 months.

Description

The procurement is for Edwards Lifesciences SAPIEN 3 ULTRA RESILIA percutaneous valves, together with the accessories and deployment systems needed for transcatheter aortic valve replacement (TAVI/TAVR) procedures. The notice states that Santé Québec Nord-de-l'Île-de-Montréal – Universitaire intends to award the contract directly to Edwards Lifesciences Canada Inc., identified as the only supplier known to meet the establishment’s clinical and technical requirements. The valves use bovine pericardial tissue treated with Resilia technology, which the notice says is intended to reduce calcification and improve durability. The stated contract duration is 36 months, with two one-year renewal periods, for a total of up to 60 months.

View original listing